KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiKabaca kalibreGüncel ima edilen olasılıkBefore Jan 1, 2031 56%6 seçenek arasında lider
Piyasa kalitesi
37 / 100
Düşük kalite24s Hacim
₺0
Likidite
₺70,6 B
Düşük likiditeAlis / Satis
10.0% / 16.0%
Spread
6.0 pt
Geniş spreadPiyasa verileri
20 dakika önce guncellendi
14 May 26 2:001 Oca 27 4:59
Trendler
Yalnızca sanal bakiye, gerçek para yokYatırım tavsiyesi değildir
Seçilen sonuç
Before Jan 1, 202710%
Hacim trendi
$22 Tem10g veri27 Tem
İlgili Piyasalar
Will the FDA approve camizestrant for advanced breast cancer?
₺2,5 BBefore Oct 1, 2026: 37%KALSHI
KALSHI
Hantavirus pandemic in 2026?
₺5,1 MnEvet: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
₺369,4 B26-27M: 83%POLYMARKET
POLYMARKET
New pandemic in 2026?
₺278,6 BEvet: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
₺131,4 BAbove 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
₺111 BEvet: 5%KALSHI
KALSHIBu konularda aktif
Kurallar
If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: